Ecklonia Cava - Fibromyalgia
Ecklonia Cava Extract (ECE): Phase 1 Clinical Trial Preliminary Results
In a 2 month, double-blinded study of recognized fibromyalgia patients, ECE was administered as an additional therapy to the patients current standard of Doctor care. The results established the general safety of ECE and
- Cut the time it took the participants to fall asleep by 47 minutes
- Aaugmented total nighttime sleep by 1.6 hours
- Improved depth of sleep by 80%
- Boosted their energy levels by70%
- Gave 2 1/4 more good days per week
- Helped decrease pain by 30%
- General condition improved by 40%.
Interestingly, these improvements were achieved at all doses. Patients given the placebo had no improvement during the study.